Skip to main content

Sevenfact FDA Approval History

Last updated by Judith Stewart, BPharm on Sep 17, 2020.

FDA Approved: Yes (First approved April 1, 2020)
Brand name: Sevenfact
Generic name: coagulation factor VIIa (recombinant)-jncw
Dosage form: Injection
Company: HEMA Biologics, LLC
Treatment for: Hemophilia A or B with Inhibitors

Sevenfact (coagulation factor VIIa [recombinant]-jncw) is a coagulation factor VIIa concentrate indicated for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors (neutralizing antibodies).

Development timeline for Sevenfact

Apr  6, 2020Approval FDA Approves Sevenfact [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.